Serina Therapeutics, Inc. 8-K

What Happened
Serina Therapeutics (filed 8-K) reported executive and governance changes: on April 20, 2026 Serina (AL), Inc. (a wholly owned subsidiary) promoted Srini Tenjarla, Ph.D. to Chief Technology Officer; his annual base salary was increased to $425,000 effective retroactively to March 15, 2026. The Company also increased CEO Steve Ledger’s annual base salary to $500,000 effective as of September 9, 2024 per his employment agreement, and the retroactive portion was paid in a lump sum in April 2026. Separately, the Board adopted amended and restated bylaws on April 15, 2026 that add provisions for Board Co-Chairs and related clarifications; the bylaws are filed as Exhibit 3.1 to the 8-K.

Key Details

• Srini Tenjarla promoted to Chief Technology Officer of Serina (AL) on April 20, 2026.
• Dr. Tenjarla’s annual base salary increased to $425,000, effective March 15, 2026.
• CEO Steve Ledger’s annual base salary increased to $500,000, effective September 9, 2024; retroactive pay paid in April 2026.
• Board adopted amended and restated bylaws on April 15, 2026; new bylaws add Co-Chair appointment/powers, clarify who may call and preside at special stockholder and Board meetings, and include other conforming updates.

Why It Matters
These items affect company leadership, governance, and near-term cash outflows. The retroactive salary payments and higher ongoing base pay increase executive compensation expense (which could modestly affect operating costs). The bylaw amendments change Board leadership mechanics—adding Co-Chairs and clarifying their authority—which may influence how board meetings and special stockholder meetings are called and presided over. Investors should view this as corporate governance and compensation updates disclosed by the company; no other financial results or transactions were reported in the filing.